Nonresponse to 18-month lamivudine monotheraphy in chronic hepatitis B patients with dual genotype B and C infection and acute exacerbation

Ming Jen Sheu; Ching Yih Lin; Chi Shu Sun; Hsing Tao Kuo; Lok Beng Koay; Chuan Lee; Jyh Jou Chen; Ling Yu Tang; Sun Lung Tsai

doi:10.1016/S0929-6646(09)60155-8

Nonresponse to 18-month lamivudine monotheraphy in chronic hepatitis B patients with dual genotype B and C infection and acute exacerbation

Ming Jen Sheu
, Ching Yih Lin
, Chi Shu Sun
, Hsing Tao Kuo
, Lok Beng Koay
, Chuan Lee
, Jyh Jou Chen
, Ling Yu Tang
, Sun Lung Tsai^*

^*Corresponding author for this work

Chi-Mei Medical Center

Research output: Contribution to journal › Journal Article › peer-review

3 Scopus citations

Abstract

Molecular epidemiologic studies have indicated the possible existence of mixed infection of different hepatitis B virus (HBV) genotypes in chronic hepatitis B (CH-B) carriers, but the effect of dual HBV genotype B and C infection on the efficacy of lamivudine therapy remains unclear. We report four CH-B patients with dual HBV genotype B and C infection and acute exacerbation who received lamivudine monotherapy for about 18 months. None of them had achieved a sustained response at the end of the 18-month trial of treatment.

Original language	English
Pages (from-to)	588-593
Number of pages	6
Journal	Journal of the Formosan Medical Association
Volume	105
Issue number	7
DOIs	https://doi.org/10.1016/S0929-6646(09)60155-8
State	Published - 07 2006
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Acute exacerbation
Chronic hepatitis B
Dual genotype infection
Hepatitis B virus
Lamivudine therapy
Sustained response

Access to Document

10.1016/S0929-6646(09)60155-8

Cite this

@article{a009b064413e4cb796833b5f88f2a125,

title = "Nonresponse to 18-month lamivudine monotheraphy in chronic hepatitis B patients with dual genotype B and C infection and acute exacerbation",

abstract = "Molecular epidemiologic studies have indicated the possible existence of mixed infection of different hepatitis B virus (HBV) genotypes in chronic hepatitis B (CH-B) carriers, but the effect of dual HBV genotype B and C infection on the efficacy of lamivudine therapy remains unclear. We report four CH-B patients with dual HBV genotype B and C infection and acute exacerbation who received lamivudine monotherapy for about 18 months. None of them had achieved a sustained response at the end of the 18-month trial of treatment.",

keywords = "Acute exacerbation, Chronic hepatitis B, Dual genotype infection, Hepatitis B virus, Lamivudine therapy, Sustained response",

author = "Sheu, \{Ming Jen\} and Lin, \{Ching Yih\} and Sun, \{Chi Shu\} and Kuo, \{Hsing Tao\} and Koay, \{Lok Beng\} and Chuan Lee and Chen, \{Jyh Jou\} and Tang, \{Ling Yu\} and Tsai, \{Sun Lung\}",

year = "2006",

month = jul,

doi = "10.1016/S0929-6646(09)60155-8",

language = "英语",

volume = "105",

pages = "588--593",

journal = "Journal of the Formosan Medical Association",

issn = "0929-6646",

publisher = "Elsevier B.V.",

number = "7",

}

TY - JOUR

T1 - Nonresponse to 18-month lamivudine monotheraphy in chronic hepatitis B patients with dual genotype B and C infection and acute exacerbation

AU - Sheu, Ming Jen

AU - Lin, Ching Yih

AU - Sun, Chi Shu

AU - Kuo, Hsing Tao

AU - Koay, Lok Beng

AU - Lee, Chuan

AU - Chen, Jyh Jou

AU - Tang, Ling Yu

AU - Tsai, Sun Lung

PY - 2006/7

Y1 - 2006/7

N2 - Molecular epidemiologic studies have indicated the possible existence of mixed infection of different hepatitis B virus (HBV) genotypes in chronic hepatitis B (CH-B) carriers, but the effect of dual HBV genotype B and C infection on the efficacy of lamivudine therapy remains unclear. We report four CH-B patients with dual HBV genotype B and C infection and acute exacerbation who received lamivudine monotherapy for about 18 months. None of them had achieved a sustained response at the end of the 18-month trial of treatment.

AB - Molecular epidemiologic studies have indicated the possible existence of mixed infection of different hepatitis B virus (HBV) genotypes in chronic hepatitis B (CH-B) carriers, but the effect of dual HBV genotype B and C infection on the efficacy of lamivudine therapy remains unclear. We report four CH-B patients with dual HBV genotype B and C infection and acute exacerbation who received lamivudine monotherapy for about 18 months. None of them had achieved a sustained response at the end of the 18-month trial of treatment.

KW - Acute exacerbation

KW - Chronic hepatitis B

KW - Dual genotype infection

KW - Hepatitis B virus

KW - Lamivudine therapy

KW - Sustained response

UR - https://www.scopus.com/pages/publications/33746952075

U2 - 10.1016/S0929-6646(09)60155-8

DO - 10.1016/S0929-6646(09)60155-8

M3 - 文章

C2 - 16877240

AN - SCOPUS:33746952075

SN - 0929-6646

VL - 105

SP - 588

EP - 593

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

IS - 7

ER -

Nonresponse to 18-month lamivudine monotheraphy in chronic hepatitis B patients with dual genotype B and C infection and acute exacerbation

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this